LONDON — GSK said Monday it would pay $500 million upfront for rights to an experimental COPD drug from Jiangsu Hengrui Pharmaceuticals, the latest example of a pharma company turning to a Chinese firm to build out its pipeline.
The deal also includes licensing options for 11 other Hengrui medicines, including those in development in immunology and oncology. If all programs are optioned and all milestones are met, the pact could be worth up to $12 billion.
The centerpiece of the agreement is HRS-9821, now in clinical studies for COPD. GSK, which recently saw its drug Nucala win approval for COPD in the U.S., said picking up HS-9821 will fuel its “ambition to treat patients across the widest spectrum of COPD,” including those who are not helped by existing medicines.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
View All Plans